<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478540</url>
  </required_header>
  <id_info>
    <org_study_id>Mic-1</org_study_id>
    <nct_id>NCT03478540</nct_id>
  </id_info>
  <brief_title>Gut Microbiota and Immune Recovery</brief_title>
  <official_title>Impact of Gut Microbiota on the Immune Recovery in HIV-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore whether gut microbiota would impact CD4 T cells recovery in HIV-infected patients
      on antiretroviral therapy (ART). We prospectively enroll patients initiate ART and collect
      their fecal at followup for one year.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune recovery</measure>
    <time_frame>48 weeks</time_frame>
    <description>Cluster of differentiation 4 (CD4) T cells increased &gt;25% or to higher than 350 cells/mm3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV viral load</measure>
    <time_frame>48 weeks</time_frame>
    <description>Viral load below limitation of detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition</measure>
    <time_frame>week 0 and 48</time_frame>
    <description>Gut microbiota composition</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV-1-infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Retroviral Agents</intervention_name>
    <description>First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients initiating antiretroviral therapy with CD4 T cell counts&lt;
        350cells/mm3
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV infection

          -  Antiretroviral therapy naive

          -  CD4 T cell counts&lt;350cells/mm3

          -  Agree to participate

        Exclusion Criteria:

          -  Don't want to start antiretroviral therapy

          -  Cocurrent cancer or opportunistic infection

          -  Liver diseases

          -  received antibiotics within four weeks of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Chen</last_name>
    <phone>021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>chenjun@shaphc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongzhou Lu</last_name>
    <phone>021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Chen</last_name>
      <phone>008602137990333</phone>
      <phone_ext>3222</phone_ext>
      <email>qtchenjun@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hongzhou Lu</last_name>
      <phone>008602137990333</phone>
      <phone_ext>3222</phone_ext>
      <email>luhongzhou@fudan.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Chen, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Vice Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

